FILTER
FILTERED INTERVIEW RESULTS
Roel Schaapveld
CEO, INTERNA TECHNOLOGIES
InteRNA is a Dutch biotechnology company specializing in the development of RNA therapeutics for the treatment of cancer.
Ravi Udaya Bhaskar
DIRECTOR GENERAL, PHARMEXCIL
India’s Pharmexcil discusses developments in the country’s pharmaceuticals segment.
Anthony Capobianco
FOUNDER AND PRESIDENT, STEMSYNERGY THERAPEUTICS
StemSynergy Therapeutics (SSTI) is a biotechnology company focused on discovering drugs that target biomolecules and cellular processes fundamental to cancer.
Manni Kantipudi & Dr. Ramesh Subramanian
CHIEF EXECUTIVE OFFICER & CHIEF COMMERCIAL OFFICER, GVK BIO
GVK BIO is a global contract research and development organization (CRDO) providing drug discovery and development services to the biopharma industry.
Ahmet Musul
CHAIRMAN, EKOL LOGISTICS
Ekol provides international freight, warehousing, distribution, foreign trade, customs, and supply-chain management services across Europe.
Ed Ikeguchi
CEO, AICURE
AiCure is an AI and advanced data analytics company targeting the health industry.
Dr. Sharvil Patel
MANAGING DIRECTOR, ZYDUS CADILA
Zydus Cadila ranks fourth in the Indian pharmaceutical industry, with a strong global presence in the U.S., Europe, Latin America and South Africa, alongside 25 other emerging markets worldwide.
Dr. Kunal Saxena
MANAGING DIRECTOR, RUSAN PHARMA
Rusan Pharma is a fully integrated pharmaceutical company specializing in the treatment of addiction and pain management.
Serkan Barış
COUNTRY PRESIDENT, ASTRAZENECA
AstraZeneca Turkey provides an overview of its Turkish operations and opinions on the market.
Prof. Dr. Tanıl Kocagöz
HEAD OF DEPARTMENTS OF MEDICAL MICROBIOLOGY AND BIOTECHNOLOGY, ACIBADEM UNIVERSITY RESEARCH LABORATORY
Acibadem University is a private university founded in 2007, belonging to the Acibadem Healthcare Group. Professor Dr Kocagöz is a microbiology and infectious disease specialist.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
